RxDoctor Payments Data

Melisa Clements

Nurse Practitioner · Pensacola, FLNPI 1093073751

Payments from drug & device makers

$975in general payments, 2019–2025

Across 25 payments — averaging $38.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alpha Cognition USA, Inc.$283
  • Otsuka America Pharmaceutical, Inc.$276
  • AstraZeneca$130
  • Acadia Pharmaceuticals Inc$106
  • Avanir Pharmaceuticals, Inc.$91
  • Lilly USA, LLC$46
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$147,350
Medicare patients
215
Services billed
1,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban330$99,946
TrulicityDulaglutide46$24,555
LinzessLinaclotide37$21,493
AptiomEslicarbazepine Acetate33$20,798
OzempicSemaglutide15$15,405
XareltoRivaroxaban37$11,703
EntrestoSacubitril/Valsartan22$7,501
Incruse ElliptaUmeclidinium Bromide18$6,852
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$6,645
FarxigaDapagliflozin Propanediol19$5,852
Atorvastatin Calcium274$5,138
Divalproex Sodium117$5,015
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$4,831
MyrbetriqMirabegron19$4,634
JardianceEmpagliflozin14$4,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$46$24,55546 claims
AstraZenecaFarxiga$130$5,85219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →